Literature DB >> 24052540

TMA: beware of complements.

Daniel Ricklin1, Douglas B Cines.   

Abstract

In this issue of Blood, Jodele and colleagues report that defective complement regulation contributes to the development of thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT) with important implications for diagnosis and management of this severe clinical complication.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24052540      PMCID： PMC3778545          DOI： 10.1182/blood-2013-07-512707

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Corey Cutler; Shelly Carter; Paul Martin; Roberta Adams; Mary Horowitz; James Ferrara; Robert Soiffer; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2005-08       Impact factor: 5.742

Review 2.  Complement activation in diseases presenting with thrombotic microangiopathy.

Authors:  Seppo Meri
Journal:  Eur J Intern Med       Date:  2013-06-04       Impact factor: 4.487

Review 3.  Thrombosis in paroxysmal nocturnal hemoglobinuria.

Authors:  Anita Hill; Richard J Kelly; Peter Hillmen
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

4.  Dimerization of complement factor H-related proteins modulates complement activation in vivo.

Authors:  Elena Goicoechea de Jorge; Joseph J E Caesar; Talat H Malik; Mitali Patel; Matthew Colledge; Steven Johnson; Svetlana Hakobyan; B Paul Morgan; Claire L Harris; Matthew C Pickering; Susan M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

Review 5.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

6.  Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Christoph Licht; Jens Goebel; Bradley P Dixon; Kejian Zhang; Theru A Sivakumaran; Stella M Davies; Fred G Pluthero; Lily Lu; Benjamin L Laskin
Journal:  Blood       Date:  2013-06-27       Impact factor: 22.113

Review 7.  Complement in immune and inflammatory disorders: therapeutic interventions.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 8.  Complement in immune and inflammatory disorders: pathophysiological mechanisms.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

9.  Antigen-presenting cell-derived complement modulates graft-versus-host disease.

Authors:  Wing-Hong Kwan; Daigo Hashimoto; Estela Paz-Artal; Katya Ostrow; Melanie Greter; Hugo Raedler; M Edward Medof; Miriam Merad; Peter S Heeger
Journal:  J Clin Invest       Date:  2012-05-15       Impact factor: 14.808

10.  Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.

Authors:  Stefan Heinen; Andrea Hartmann; Nadine Lauer; Ulrike Wiehl; Hans-Martin Dahse; Sylvia Schirmer; Katharina Gropp; Tina Enghardt; Reinhard Wallich; Steffi Hälbich; Michael Mihlan; Ursula Schlötzer-Schrehardt; Peter F Zipfel; Christine Skerka
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113
  10 in total
  9 in total

1.  The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Kejian Zhang; Fanggeng Zou; Benjamin Laskin; Christopher E Dandoy; Kasiani C Myers; Adam Lane; Jaroslav Meller; Mario Medvedovic; Jenny Chen; Stella M Davies
Journal:  Blood       Date:  2015-11-24       Impact factor: 22.113

Review 2.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

Review 3.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

4.  A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.

Authors:  Christopher E Dandoy; Seth Rotz; Priscila Badia Alonso; Anna Klunk; Catherine Desmond; John Huber; Hannah Ingraham; Christine Higham; Christopher C Dvorak; Christine Duncan; Michelle Schoettler; Leslie Lehmann; Maria Cancio; James Killinger; Blachy Davila; Rachel Phelan; Kris M Mahadeo; Sajad Khazal; Nahal Lalefar; Madhav Vissa; Kasiani Myers; Greg Wallace; Adam Nelson; Pooja Khandelwal; Deepika Bhatla; Nicholas Gloude; Eric Anderson; Jeffrey Huo; Philip Roehrs; Jeffery J Auletta; Ranjit Chima; Adam Lane; Stella M Davies; Sonata Jodele
Journal:  Blood Adv       Date:  2021-01-12

5.  High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.

Authors:  Sonata Jodele; Christopher E Dandoy; Kasiani Myers; Gregory Wallace; Adam Lane; Ashley Teusink-Cross; Brian Weiss; Stella M Davies
Journal:  Bone Marrow Transplant       Date:  2018-04-19       Impact factor: 5.483

6.  Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study.

Authors:  Li-Ping Yang; Peng Zhao; Ye-Jun Wu; Hai-Xia Fu; Yun He; Xiao-Dong Mo; Meng Lv; Feng-Rong Wang; Chen-Hua Yan; Yu-Hong Chen; Ying-Jun Chang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Bone Marrow Transplant       Date:  2022-01-25       Impact factor: 5.483

7.  Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.

Authors:  Sonata Jodele; Tsuyoshi Fukuda; Kana Mizuno; Alexander A Vinks; Benjamin L Laskin; Jens Goebel; Bradley P Dixon; Ranjit S Chima; Russel Hirsch; Ashley Teusink; Danielle Lazear; Adam Lane; Kasiani C Myers; Christopher E Dandoy; Stella M Davies
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-09       Impact factor: 5.742

8.  Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Tsuyoshi Fukuda; Alexander Vinks; Kana Mizuno; Benjamin L Laskin; Jens Goebel; Bradley P Dixon; Ashley Teusink; Fred G Pluthero; Lily Lu; Christoph Licht; Stella M Davies
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-25       Impact factor: 5.742

Review 9.  Thrombotic microangiopathy following haematopoietic stem cell transplant.

Authors:  Eleanor G Seaby; Rodney D Gilbert
Journal:  Pediatr Nephrol       Date:  2017-10-09       Impact factor: 3.714
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.